The design of retroviral vectors used in the CAR-T products, risk management, and future perspective

Abstract

Chimeric antigen receptor T-cell (CAR-T) therapy is a revolutionary approach in cancer treatment. More than 10 CAR-T products have already approved on market worldly wide, and they use either gamma retroviral vectors or lentiviral vectors to deliver the CAR gene. Both vectors have the ability to effectively and persistently integrate the CAR gene into T cells. Despite the advancements in CAR-T therapy, the potential risks associated with the vectors, particularly the risks of the secondary malignancies, still remain as a concern. This article compares the characteristics of gamma retroviral and lentiviral vectors, discusses the development of vector packaging systems, and examines the design of self-inactivating (SIN) vectors. It also addresses the risks of secondary malignancies that might possibly be associated with the retroviral vectors, and the strategies to decrease the risks and increase the safer clinical use of the vectors. This article also discusses the current regulatory landscape and management approaches aiming to mitigate these risks through stringent safety measures and ongoing monitoring. Future perspectives focus on improving the safety profiles of the vectors and broadening their scope of use. The article provides a thorough overview of the most recent research discoveries and regulatory updates in the field of CAR-T therapy, highlighting the significance of a balanced strategy that strikes a balance between innovation and patient safety in the development and implementation of CAR-T therapy.

Keywords

CAR-T therapy / replication-competent retroviruses (RCR) / retroviral vectors / risk management / secondary malignancies / SIN vectors

References

[1] Pan K, Farrukh H, Chittepu VCSR, Xu H, Pan CX, Zhu Z. CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy. J Exp Clin Cancer Res. 2022; 41(1): 119.

[2] Prasad V. Tisagenlecleucel—the first approved CAR-T-cell therapy: implications for payers and policy makers. Nat Rev Clin Oncol. 2018; 15(1): 11-12.

[3] Schuster SJ, Bishop MR, Tam CS, et al. Long-term follow-up of tisagenlecleucel in adult patients with relapsed or refractory diffuse large B-cell lymphoma: updated analysis of Juliet study. Biol Blood Marrow Transplant. 2019; 25(3): S20-S21.

[4] Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018; 378(5): 439-448.

[5] Bishop MR, Maziarz RT, Waller EK, et al. Tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma patients without measurable disease at infusion. Blood Adv. 2019; 3(14): 2230-2236.

[6] Locke FL, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. N Engl J Med. 2022; 386(7): 640-654.

[7] Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017; 377(26): 2531-2544.

[8] Roberts ZJ, Better M, Bot A, Roberts MR, Ribas A. Axicabtagene ciloleucel, a first-in-class CAR T cell therapy for aggressive NHL. Leuk Lymphoma. 2018; 59(8): 1785-1796.

[9] Wang M, Munoz J, Goy A, et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2020; 382(14): 1331-1342.

[10] Wang Y, Jain P, Locke FL, et al. Brexucabtagene autoleucel for relapsed/refractory mantle cell lymphoma: real world experience from the US lymphoma CAR T consortium. Blood. 2021; 138(1): 744-744.

[11] Bouchkouj N, Lin X, Wang X, et al. FDA approval summary: brexucabtagene autoleucel for treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. Oncologist. 2022; 27(10): 892-899.

[12] Kamdar M, Solomon SR, Arnason JE, et al. Lisocabtagene maraleucel (liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, versus standard of care (SOC) with salvage chemotherapy (CT) followed by autologous stem cell transplantation (ASCT) as second-line (2L) treatment in patients (Pts) with relapsed or refractory (R/R) large B-cell lymphoma (LBCL): results from the randomized phase 3 transform study. Blood. 2021; 138(1): 91-91.

[13] Abramson JS, Palomba ML, Gordon LI, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020; 396(10254): 839-852.

[14] Teoh J, Brown LF. Developing lisocabtagene maraleucel chimeric antigen receptor T-cell manufacturing for improved process, product quality and consistency across CD19+ hematologic indications. Cytotherapy. 2022; 24(9): 962-973.

[15] Anderson Jr LD. Idecabtagene vicleucel (ide-cel) CAR T-cell therapy for relapsed and refractory multiple myeloma. Future Oncol. 2022; 18(3): 277-289.

[16] Munshi NC, Anderson LD, Shah N, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021; 384(8): 705-716.

[17] Friedman KM, Garrett TE, Evans JW, et al. Effective targeting of multiple B-cell maturation antigen–expressing hematological malignances by anti-B-cell maturation antigen chimeric antigen receptor T cells. Hum Gene Ther. 2018; 29(5): 585-601.

[18] Berdeja JG, Madduri D, Usmani SZ, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet. 2021; 398(10297): 314-324.

[19] Martin T, Usmani SZ, Berdeja JG, et al. Ciltacabtagene autoleucel, an anti–B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed/refractory multiple myeloma: CARTITUDE-1 2-year follow-up. J Clin Oncol. 2023; 41(6): 1265-1274.

[20] Chekol Abebe E, Yibeltal Shiferaw M, Tadele Admasu F, Asmamaw Dejenie T. Ciltacabtagene autoleucel: the second anti-BCMA CAR T-cell therapeutic armamentarium of relapsed or refractory multiple myeloma. Front Immunol. 2022; 13: 991092.

[21] Lu J, Xu L, Wei W, He W. Advanced therapy medicinal products in China: regulation and development. MedComm. 2023; 4(3): e251.

[22] Ying Z, Yang H, Guo Y, et al. Relmacabtagene autoleucel (relma-cel) CD19 CAR-T therapy for adults with heavily pretreated relapsed/refractory large B-cell lymphoma in China. Cancer Med. 2021; 10(3): 999-1011.

[23] Mu W, Long X, Cai H, et al. A model perspective explanation of the long-term sustainability of a fully human BCMA-targeting CAR (CT103A) T-Cell immunotherapy. Front Pharmacol. 2022; 13: 803693.

[24] Wang D, Wang J, Hu G, et al. A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed/refractory multiple myeloma. Blood. 2021; 137(21): 2890-2901.

[25] Qin C, Tian DS, Zhou LQ, et al. Anti-BCMA CAR T-cell therapy CT103A in relapsed or refractory AQP4-IgG seropositive neuromyelitis optica spectrum disorders: phase 1 trial interim results. Signal Transduct Target Ther. 2023; 8(1): 5.

[26] Gu R, Liu F, Zou D, et al. Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia. J Hematol OncolJ Hematol Oncol. 2020; 13(1): 122.

[27] Chen W, Fu C, Fang B, et al. Phase II study of fully human BCMA-targeting CAR-T cells (zevorcabtagene autoleucel) in patients with relapsed/refractory multiple myeloma. Blood. 2022; 140(1): 4564-4565.

[28] Fu C, Chen W, Cai Z, et al. Three-year follow-up on efficacy and safety results from phase 1 lummicar study 1 of zevorcabtagene autoleucel in Chinese patients with relapsed or refractory multiple myeloma. Blood. 2023; 142(1): 4845-4845.

[29] Cappell KM, Kochenderfer JN. A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains. Nat Rev Clin Oncol. 2021; 18(11): 715-727.

[30] Hwang LH, Gilboa E. Expression of genes introduced into cells by retroviral infection is more efficient than that of genes introduced into cells by DNA transfection. J Virol. 1984; 50(2): 417-424.

[31] Anson DS. The use of retroviral vectors for gene therapy-what are the risks? A review of retroviral pathogenesis and its relevance to retroviral vector-mediated gene delivery. Genet Vaccines Ther. 2004; 2(1): 9.

[32] Baum C, Düllmann J, Li Z, et al. Side effects of retroviral gene transfer into hematopoietic stem cells. Blood. 2003; 101(6): 2099-2113.

[33] Yi Y, Hahm S, Lee K. Retroviral gene therapy: safety issues and possible solutions. Curr Gene Ther. 2005; 5(1): 25-35.

[34] Schlimgen R, Howard J, Wooley D, et al. Risks associated with lentiviral vector exposures and prevention strategies. J Occup Environ Med. 2016; 58(12): 1159-1166.

[35] Milone MC, O’Doherty U. Clinical use of lentiviral vectors. Leukemia. 2018; 32(7): 1529-1541.

[36] Poletti V, Mavilio F. Designing lentiviral vectors for gene therapy of genetic diseases. Viruses. 2021; 13(8): 1526.

[37] Watanabe N, McKenna MK. Generation of CAR T-cells using gamma retroviral vector. Methods in Cell Biology. 2022; 167: 171-183.

[38] Maetzig T, Galla M, Baum C, Schambach A. Gammaretroviral vectors: biology, technology and application. Viruses. 2011; 3(6): 677-713.

[39] Modlich U, Navarro S, Zychlinski D, et al. Insertional transformation of hematopoietic cells by self-inactivating lentiviral and gammaretroviral vectors. Mol Ther. 2009; 17(11): 1919-1928.

[40] Rodrigues AF, Alves PM, Coroadinh A. Production of retroviral and lentiviral gene therapy vectors: challenges in the manufacturing of lipid enveloped virus. In: Xu K, ed. Viral Gene Therapy. Tech; 2011. doi:10.5772/18615

[41] Ghani K, Boivin-Welch M, Roy S, et al. Generation of high-titer self-inactivated gamma retroviral vector producer cells. Mol Ther—Methods Clin Dev. 2019; 14: 90-99.

[42] Loew R, Meyer Y, Kuehlcke K, et al. A new PG13-based packaging cell line for stable production of clinical-grade self-inactivating gamma retroviral vectors using targeted integration. Gene Ther. 2010; 17(2): 272-280.

[43] Tomás HA, Rodrigues AF, Carrondo MJT, Coroadinha AS. LentiPro26: novel stable cell lines for constitutive lentiviral vector production. Sci Rep. 2018; 8(1): 5271.

[44] Naldini L, Blömer U, Gallay P, et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science. 1996; 272(5259): 263-267.

[45] Ferreira MV, Cabral ET, Coroadinha AS. Progress and perspectives in the development of lentiviral vector producer cells. Biotechnol J. 2021; 16(1): 2000017.

[46] Vannucci L, Lai M, Chiuppesi F, Ceccherini-Nelli L, Pistello M. Viral vectors: a look back and ahead on gene transfer technology. New Microbiol. 2013; 36(1): 1-22.

[47] Labbé RP, Vessillier S, Rafiq QA. Lentiviral vectors for T cell engineering: clinical applications, bioprocessing and future perspectives. Viruses. 2021; 13(8): 1528.

[48] Barajas BC, Tanaka M, Robinson BA, et al. Identifying the assembly intermediate in which Gag first associates with unspliced HIV-1 RNA suggests a novel model for HIV-1 RNA packaging. PLOS Pathog. 2018; 14(4): e1006977.

[49] Yu FH, Huang KJ, Wang CT. HIV-1 mutant assembly, processing and infectivity expresses pol independent of Gag. Viruses. 2020; 12(1): 54.

[50] Ory DS, Neugeboren BA, Mulligan RC. A stable human-derived packaging cell line for production of high titer retrovirus/vesicular stomatitis virus G pseudotypes. Proc Natl Acad Sci. 1996; 93(21): 11400-11406.

[51] Walther W, Stein U. Viral vectors for gene transfer: a review of their use in the treatment of human diseases. Drugs. 2000; 60(2): 249-271.

[52] Fernandes J, Jayaraman B, Frankel A. The HIV-1 Rev response element: an RNA scaffold that directs the cooperative assembly of a homo-oligomeric ribonucleoprotein complex. RNA Biol. 2012; 9(1): 6-11.

[53] Browning D, Trobridge G. Insulators to improve the safety of retroviral vectors for HIV gene therapy. Biomedicines. 2016; 4(1): 4.

[54] Emery DW. The use of chromatin insulators to improve the expression and safety of integrating gene transfer vectors. Hum Gene Ther. 2011; 22(6): 761-774.

[55] Gutierrez-Guerrero A, Cosset FL, Verhoeyen E. Lentiviral vector pseudotypes: precious tools to improve gene modification of hematopoietic cells for research and gene therapy. Viruses. 2020; 12(9): 1016.

[56] Humbert O, Gisch DW, Wohlfahrt ME, et al. Development of third-generation cocal envelope producer cell lines for robust lentiviral gene transfer into hematopoietic stem cells and T-cells. Mol Ther. 2016; 24(7): 1237-1246.

[57] Gurumoorthy N, Nordin F, Tye GJ, Wan Kamarul Zaman WS, Ng MH. Non-integrating lentiviral vectors in clinical applications: a glance through. Biomedicines. 2022; 10(1): 107.

[58] Bulcha JT, Wang Y, Ma H, Tai PWL, Gao G. Viral vector platforms within the gene therapy landscape. Signal Transduct Target Ther. 2021; 6(1): 53.

[59] Zufferey R, Dull T, Mandel RJ, et al. Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J Virol. 1998; 72(12): 9873-9880.

[60] Yu SF, Von Rüden T, Kantoff PW, et al. Self-inactivating retroviral vectors designed for transfer of whole genes into mammalian cells. Proc Natl Acad Sci. 1986; 83(10): 3194-3198.

[61] Yee JK, Moores JC, Jolly DJ, Wolff JA, Respess JG, Friedmann T. Gene expression from transcriptionally disabled retroviral vectors. Proc Natl Acad Sci. 1987; 84(15): 5197-5201.

[62] Zufferey R, Donello JE, Trono D, Hope TJ. Woodchuck hepatitis virus posttranscriptional regulatory element enhances expression of transgenes delivered by retroviral vectors. J Virol. 1999; 73(4): 2886-2892.

[63] Higashimoto T, Urbinati F, Perumbeti A, et al. The woodchuck hepatitis virus post-transcriptional regulatory element reduces readthrough transcription from retroviral vectors. Gene Ther. 2007; 14(17): 1298-1304.

[64] Reichenbach P, Giordano Attianese GMP, Ouchen K, et al. A lentiviral vector for the production of T cells with an inducible transgene and a constitutively expressed tumour-targeting receptor. Nat Biomed Eng. 2023; 7: 1063-1080.

[65] Zanta-Boussif MA, Charrier S, Brice-Ouzet A, et al. Validation of a mutated PRE sequence allowing high and sustained transgene expression while abrogating WHV-X protein synthesis: application to the gene therapy of WAS. Gene Ther. 2009; 16(5): 605-619.

[66] Mosier DE. Introduction for “safety considerations for retroviral vectors: a short review”. Appl Biosaf. 2004; 9(2): 68-75.

[67] Morgan MA, Galla M, Grez M, Fehse B, Schambach A. Retroviral gene therapy in Germany with a view on previous experience and future perspectives. Gene Ther. 2021; 28(9): 494-512.

[68] Rintz E, Higuchi T, Kobayashi H, Galileo DS, Wegrzyn G, Tomatsu S. Promoter considerations in the design of lentiviral vectors for use in treating lysosomal storage diseases. Mol Ther—Methods Clin Dev. 2022; 24: 71-87.

[69] European Medicines Agency. Assessment report of Kymriah. https://www.ema.europa.eu/en/medicines/human/EPAR/kymriah

[70] FDA. FDA investigating serious risk of T-cell malignancy following BCMA-directed or CD19-directed autologous chimeric antigen receptor (CAR) T cell immunotherapies. FDA. Published online November 28, 2023. Accessed January 26, 2024. https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/fda-investigating-serious-risk-t-cell-malignancy-following-bcma-directed-or-cd19-directed-autologous

[71] FDA. 2024 Safety and availability communications. FDA. Published online January 24, 2024. Accessed January 26, 2024. https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/2024-safety-and-availability-communications

[72] Verdun N, Marks P. Secondary cancers after chimeric antigen receptor T-cell therapy. N Engl J Med. 2024:NEJMp2400209.

[73] Ozdemirli M, Loughney TM, Deniz E, et al. Indolent CD4+ CAR T-cell lymphoma after Cilta-cel CAR T-cell therapy. N Engl J Med. 2024; 390(22): 2074-2082.

[74] Hamilton MP, Sugio T, Noordenbos T, et al. Risk of second tumors and T-cell lymphoma after CAR T-cell therapy. N Engl J Med. 2024; 390(22): 2047-2060.

[75] Mitchell E, Vassiliou GS. T-cell cancer after CAR T-cell therapy. N Engl J Med. 2024; 390(22): 2120-2121.

[76] McCormack MP, Forster A, Drynan L, Pannell R, Rabbitts TH. The LMO2 T-cell oncogene is activated via chromosomal translocations or retroviral insertion during gene therapy but has no mandatory role in normal T-cell development. Mol Cell Biol. 2003; 23(24): 9003-9013.

[77] Hacein-Bey-Abina S, Von Kalle C, Schmidt M, et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science. 2003; 302(5644): 415-419.

[78] Hacein-Bey-Abina S, Garrigue A, Wang GP, et al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest. 2008; 118(9): 3132-3142.

[79] Schambach A, Zychlinski D, Ehrnstroem B, Baum C. Biosafety features of lentiviral vectors. Hum Gene Ther. 2013; 24(2): 132-142.

[80] Micklethwaite KP, Gowrishankar K, Gloss BS, et al. Investigation of product-derived lymphoma following infusion of piggyBac - modified CD19 chimeric antigen receptor T cells. Blood. 2021; 138(16): 1391-1405.

[81] Harrison SJ, Nguyen T, Rahman M, et al. CAR+ T-cell lymphoma post ciltacabtagene autoleucel therapy for relapsed refractory multiple myeloma. Blood. 2023; 142(1): 6939-6939.

[82] FDA. Long term follow-up after administration of human gene therapy products; guidance for industry. 2020. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/long-term-follow-after-administration-human-gene-therapy-products

[83] European Medicines Agency. Guideline on quality, non-clinical and clinical aspects of medicinal products containing genetically modified cells. 2020. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-quality-non-clinical-and-clinical-aspects-medicinal-products-containing-genetically-modified-cells-revision-1_en.pdf

[84] Center for Biologics Evaluation and Research. Frequently asked questions — developing potential cellular and gene therapy products. November 25, 2024. Accessed November 28, 2024. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/frequently-asked-questions-developing-potential-cellular-and-gene-therapy-products

[85] Vanin EF, Kaloss M, Broscius C, Nienhuis AW. Characterization of replication-competent retroviruses from nonhuman primates with virus-induced T-cell lymphomas and observations regarding the mechanism of oncogenesis. J Virol. 1994; 68(7): 4241-4250.

[86] Donahue RE, Kessler SW, Bodine D, et al. Helper virus induced T cell lymphoma in nonhuman primates after retroviral mediated gene transfer. J. Exp Med. 1992; 176: 1125-1135.

[87] FDA. Testing of retroviral vector-based human gene therapy products for replication competent retrovirus during product manufacture and patient follow-up; guidance for industry. 2020. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/testing-retroviral-vector-based-human-gene-therapy-products-replication-competent-retrovirus-during

[88] FDA. Chemistry, manufacturing, and control (CMC) information for human gene therapy investigational new drug applications (INDs); guidance for industry. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/chemistry-manufacturing-and-control-cmc-information-human-gene-therapy-investigational-new-drug

[89] Martineau D, Klump WM, McCormack JE, et al. Evaluation of PCR and ELISA assays for screening clinical trial subjects for replication-competent retrovirus. Hum Gene Ther. 1997; 8(10): 1231-1241.

[90] Long Z, Li LP, Grooms T, et al. Biosafety monitoring of patients receiving intracerebral injections of murine retroviral vector producer cells. Hum Gene Ther. 1998; 9(8): 1165-1172.

[91] Cornetta K, Duffy L, Feldman SA, et al. Screening clinical cell products for replication competent retrovirus: the national gene vector biorepository experience. Mol Ther—Methods Clin Dev. 2018; 10: 371-378.

[92] Cornetta K, Yao J, House K, et al. Replication competent retrovirus testing (RCR) in the National Gene Vector Biorepository: no evidence of RCR in 1, 595 post-treatment peripheral blood samples obtained from 60 clinical trials. Mol Ther. 2023; 31(3): 801-809.

[93] Cornetta K, Lin TY, Pellin D, Kohn DB. Meeting FDA Guidance recommendations for replication-competent virus and insertional oncogenesis testing. Mol Ther—Methods Clin Dev. 2023; 28: 28-39.

[94] Eisenman D, Swindle S. Food and Drug Administration guidance on design of clinical trials for gene therapy products with potential for genome integration or genome editing and associated long-term follow-up of research subjects. Appl Biosaf. 2022; 27(4): 201-209.

[95] Nelson R. FDA investigating safety risks in CAR T-cell recipients. Lancet. 2023; 402(10418): 2181.

[96] Prasad V. T-cell lymphoma from CAR T-cell therapy—a new safety notice. JAMA. 2024; 331: 389-390..

[97] Levine BL, Pasquini MC, Connolly JE, et al. Unanswered questions following reports of secondary malignancies after CAR-T cell therapy. Nat Med. 2024; 30(2): 338-341.

[98] Lareau CA, Yin Y, Maurer K, et al. Latent human herpesvirus 6 is reactivated in CAR T cells. Nature. 2023; 623(7987): 608-615.

[99] Cheng J, Huang J, Cao W, et al. Case report: fatal cytomegalovirus pneumonia after CAR-T cell therapy in the long-term follow-up. Front Immunol. 2023; 14: 1226148.

[100] Ruella M, Xu J, Barrett DM, et al. Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell. Nat Med. 2018; 24(10): 1499-1503.

[101] Aghajanian H, Rurik JG, Epstein JA. CAR-based therapies: opportunities for immuno-medicine beyond cancer. Nat Metab. 2022; 4(2): 163-169.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.